Clinical Trials Logo

Pulmonary Embolism clinical trials

View clinical trials related to Pulmonary Embolism.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05172115 Terminated - Pulmonary Embolism Clinical Trials

Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE

CANARY
Start date: December 22, 2018
Phase: Phase 3
Study type: Interventional

In an open-label parallel groups blinded-endpoint randomized clinical trial, the investigators aim to assess the safety and efficacy of conventional catheter-directed thrombolysis (CDT) vs anticoagulation monotherapy on outcomes of patients with acute intermediate-high risk pulmonary embolism. The investigators hypothesize that CDT will have a superior efficacy and safety compared with anticoagulation-only therapy regarding the proportion of patients with a right ventricle to left ventricle (RV/LV) ratio > 0.9 at a 3-month follow-up by an imaging core laboratory, major bleeding, severe thrombocytopenia, or vascular access complication.

NCT ID: NCT04558125 Terminated - Pulmonary Embolism Clinical Trials

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

Start date: September 8, 2020
Phase: Phase 4
Study type: Interventional

- There is a knowledge gap associated with the management of patients with COVID-19 lung injury and a laboratory picture compatible with disseminated intravascular coagulation (DIC). Clinical data to date support that COVID-19 is associated with a prothrombotic state that is not simply explained by an influx of more critically ill individuals. - These patients suffer from severe respiratory failure; hypoxemia and ventilator dependence are the primary concerns; ARDS with respiratory failure is frequently the cause of death. Macroscopic and probable microvascular thromboembolic events are a major concern in this population. - When DIC is associated with COVID-19, it predicts a very poor prognosis. - This study will evaluate the clinical efficacy and safety of low-dose IV bolus tenecteplase (TNK) together with anticoagulation compared with control patients on therapeutic anticoagulation alone in hospitalized adults diagnosed with COVID-19 and acute intermediate-risk PE. - Prospective, multicenter, randomized two-arm trial enrolling consecutive patients who meet enrollment criteria. - The study will generate evidence that low-dose TNK together with anticoagulation is beneficial in these patients

NCT ID: NCT04400799 Terminated - COVID-19 Clinical Trials

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

Start date: June 15, 2020
Phase: Phase 3
Study type: Interventional

The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.

NCT ID: NCT03988842 Terminated - Pulmonary Embolism Clinical Trials

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

SAFE-LYSE
Start date: July 25, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine the degree to which pulmonary embolism (clot) can be dissolved when treated with a very low dose of a systemic thrombolytic drug (clot buster) along with standard anticoagulant therapy as compared to the standard of care anticoagulant therapy alone.

NCT ID: NCT03935178 Terminated - Clinical trials for Acute Coronary Syndrome

Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities

UVRV
Start date: August 5, 2019
Phase:
Study type: Observational

The primary purpose of this study is to evaluate the diagnostic performance of three methods for measuring right ventricular size and function including the Philips Novel RV quantification technologies (RV Heart Model volumetric analysis and Philips 2D strain) and the Upper Valley Right Ventricle Algorithm (UVRV) algorithm as compared to the gold standard of volumetric analysis via cardiac magnetic resonance imaging (CMR) in a broad patient population.

NCT ID: NCT03525535 Terminated - Pulmonary Embolism Clinical Trials

Prevalence Rate of Pulmonary Embolism Among Not Anticoagulated Patients

MAXIME
Start date: June 14, 2018
Phase:
Study type: Observational

The purpose of this study is to evaluate the prevalence rate of pulmonary embolism among not anticoagulated patient older than 75 years old admitted with syncope and hospitalised in the Toulon Hospital

NCT ID: NCT03274401 Terminated - Atrial Fibrillation Clinical Trials

Screening for Atrial Fibrillation in Pulmonary Embolism Study -SAFE-PE Study

SAFE-PE
Start date: September 13, 2017
Phase: N/A
Study type: Interventional

Patients with newly diagnosed pulmonary embolism and high thromboembolic risk will be randomized to screening for atrial fibrillation or standard of care using intermittent ECG registration for at least two weeks.

NCT ID: NCT03006562 Terminated - Prostate Cancer Clinical Trials

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

PREVENTER
Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).

NCT ID: NCT03002467 Terminated - Pulmonary Embolism Clinical Trials

Impact Analysis of Prognostic Stratification for Pulmonary Embolism

iAPP
Start date: September 2016
Phase: N/A
Study type: Interventional

The Investigator postulate that the use of PESI in addition to routine clinical practice, as opposed to routine clinical practice based on clinical judgment alone, will help physicians to correctly identify PE patients at low-risk of adverse outcomes. Considered that low-risk patients could benefit from a short hospital stay, aim of this study is to demonstrate that the use of PESI will lead physicians to discharge these patients earlier, thus reducing the duration of hospital stay of PE patients (primary outcome). Outpatients diagnosed with PE at the emergency department (ED) and admitted to participating units represent the target population As the availability of DOACs may influence the duration of hospital stay, the secondary objectives of the present study are: 1. to demonstrate that a shorter hospital stay for low-risk PE patients (independently on the method used to identify them) will reduce the incidence of hospital-associated complications and improve patients satisfaction and quality of life, without increasing the incidence of PE-related complications 2. to demonstrate that the use of PESI, as opposed to clinical judgment alone, will be associated with a greater proportion of patients discharged early (< 72 hours from ED admission) or treated entirely at home (< 24 hours from ED admission). 3. to demonstrate that the use of DOACs will reduce the duration of hospital stay of PE patients 4. to demonstrate that the use of DOACs, as opposed to standard treatment, will be associated with a greater proportion of patients discharged early (< 72 hours from ED admission) or treated entirely at home (< 24 hours from ED admission).

NCT ID: NCT02843243 Terminated - Pulmonary Embolism Clinical Trials

Validation of Different Risk Assessment Strategies in Normotensive Pulmonary Embolism

Start date: December 2016
Phase:
Study type: Observational

A risk stratification in hemodynamically stable patients with acute pulmonary embolism (PE) is deemed necessary to guide patient management. With the aim to improve the positive predictive value (PPV) for PE-related adverse events in in normotensive patients, a number of scores combining multiple risk-factors have been published. In addition, an algorithm for the risk-stratification of patients with PE has been proposed by the European society of cardiology. None but one of these scores underwent external and prospective validation. The aim of this study is to externally and prospectively validate the PPV for PE-related adverse events of the Bova score and modified FAST score in a large multicenter cohort.